The most important prognostic factor for pseudomyxoma peritonei (PMP) is the completeness of cytoreduction or the ability to remove all visible tumour nodules during the cytoreductive surgery.
The completeness of cytoreduction (CCR) was assessed using the CCR Score. Index that quantifies the extent of residual disease at the end of the procedure is classified into 4 categories:
- CCR0 (no macroscopic residual disease)
- CCR1 (residual tumours less than 2.5 mm)
- CCR2 (residual tumours between 2.5 mm and 2.5 cm)
- CCR3 (residual tumours greater than 2.5 cm)
| CC0 | No disease | |
| CC1 | present -> 0.25cm |  |
| CC2 | 0.25cm -> 2.5cm |  |
| CC3 | >2.5cm |  |
Studies have shown that patients with a complete cytoreduction (CCR-0 or CCR-1) have better long-term survival rates compared to those with incomplete cytoreduction (CCR-2 or CCR-3).
The histologic grade and subtype of the tumour, along with the patient’s age and general state of health, are additional prognostic markers. The most important element in determining the long-term prognosis of PMP patients, however, continues to be the completeness of cytoreduction.
More FAQs
What are some of the factors that can impact the prognosis for PMP?
There are several factors that can impact the prognosis for Pseudomyxoma peritonei (PMP), including the histological grade of the tumour
What is goblet cell adencarcinoma
Goblet cell adenocarcinoma is a rare type of cancer that arises from cells that are normally present in the lining of the appendix.
How is HIPEC different than traditional chemotherapy?
HIPEC is a special kind of chemotherapy that is used to treat cancer in the abdomen.
References
Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis...
Jo MH, Suh JW, Yun JS, Namgung H, Park D-G. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal cancer: 2-year follow-up results at a single institution in Korea. Annals of Surgical Treatment and Research. 2016;91(4):157. doi:10.4174/astr.2016.91.4.157
Consensuses and controversies on Pseudomyxoma Peritonei:...
Lin Y-L, Xu D-Z, Li X-B, et al. Consensuses and controversies on Pseudomyxoma Peritonei: A review of the published consensus statements and Guidelines. Orphanet Journal of Rare Diseases. 2021;16(1). doi:10.1186/s13023-021-01723-6
Written by: the Pseudomyxoma Survivor editorial team